We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Suprabasal acantholytic dermatologic toxicities associated checkpoint inhibitor therapy: A spectrum of immune reactions from paraneoplastic pemphigus‐like to Grover‐like lesions.
- Authors
Chen, Wei‐Shen; Tetzlaff, Michael T.; Diwan, Hafeez; Jahan‐Tigh, Richard; Diab, Adi; Nelson, Kelly; Glitza, Isabella C.; Kaunitz, Genevieve J.; Johnson, Daniel; Torres‐Cabala, Carlos; Pacha, Omar; Taube, Janis M.; Maloney, Kudakwashe; Prieto, Victor G.; Curry, Jonathan L.
- Abstract
Checkpoint inhibitors (CPIs) restore the function of effector immunocytes to target and destroy cancer cells. Immune‐related adverse events (irAEs) are a consequence of immune reactivation, with unpredictable inflammatory response, loss of self‐tolerance, and development of autoimmunity. Adverse events from CPIs that present as dermatologic toxicities have diverse clinical and histopathologic features. CPI‐associated dermatologic toxicities may exhibit histopathologic features of lichenoid dermatitis, bullous pemphigoid, and granulomatous/sarcoid‐like reactions. Suprabasal acantholytic dermatologic toxicities associated with CPIs are particularly rare but represent an emerging histopathologic pattern and include lichenoid dermatitis with suprabasal acantholysis/vesicle formation to Grover disease (transient acantholytic dermatosis). Here, we report two patients who developed suprabasal acantholytic dermatologic toxicities during CPI therapy. One patient exhibited a CPI‐associated autoimmune blistering disease with paraneoplastic pemphigus (PNP)‐like features restricted to histopathology and immunofluorescence, while the other patient had Grover‐like lesions. A review of the literature revealed a spectrum of suprabasal acantholytic dermatologic toxicities associated CPIs that may present as lichenoid dermatitis with acantholysis/vesicle formation, Grover‐like eruptions, and lesions with PNP‐like features restricted to histopathology and immunofluorescence. It is important for clinicians and pathologists to recognize the types of dermatologic toxicities associated with CPIs to direct appropriate therapeutic strategies.
- Subjects
PARANEOPLASTIC syndromes; CANCER cells; DERMATOLOGY; PEMPHIGUS; AUTOIMMUNE diseases
- Publication
Journal of Cutaneous Pathology, 2018, Vol 45, Issue 10, p764
- ISSN
0303-6987
- Publication type
Case Study
- DOI
10.1111/cup.13312